Warning: The NCBI web site requires JavaScript to function. more...
Department of Neonatal and Developmental Medicine, Stanford University, 750 Welch Road, Suite315, Palo Alto, CA 94304, USA. dennery@stanford.edu
In the neonate, hyperbilirubinaemia is usually due to a combination of an increased bilirubin load and decreased bilirubin elimination. Despite an understanding of the enzymatic pathways leading to bilirubin production and elimination, very few pharmacological interventions to prevent hyperbilirubinaemia are utilized and the mainstay of treatment remains phototherapy. Previously studied pharmacological agents such as D-penicillamine, phenobarbital and clofibrate may yet prove useful. Recent clinical trials using metalloporphyrins to inhibit heme catabolism and bilirubin production provides a novel pharmacological intervention for the treatment of neonatal jaundice. The safety and efficacy of these therapies will need to be confirmed prior to widespread use.
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on